NovoCure Ltd (NASDAQ: NVCR) stock closed at $16.75 on 9/3/24 after a major decline of -13.8%. Moreover, exceptionally high trading volume at 204% of normal accompanied the decline. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -7.0% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, NVCR is expected to continue to be Value Creation neutral.
NovoCure has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. NovoCure has a very low Appreciation Score of 8 but a very high Power Rating of 90, producing the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment